The single nucleotide polymorphism rs700518 is an independent risk factor for metabolic syndrome and benign prostatic hyperplasia (MetS-BPH)

scientific article published on 05 June 2018

The single nucleotide polymorphism rs700518 is an independent risk factor for metabolic syndrome and benign prostatic hyperplasia (MetS-BPH) is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1111/ANDR.12498
P932PMC publication ID6646917
P698PubMed publication ID29873201

P2093author name stringM Li
Q Xu
X Li
C Chen
T Liu
C J Chen
Y Yan
T Song
Z P Chen
C H Zou
S C Zhao
P2860cites workThe prevalence of benign prostatic hyperplasia in mainland China: evidence from epidemiological surveysQ28082321
History of aromatase: saga of an important biological mediator and therapeutic targetQ28242399
Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific StatementQ29619465
Mining disease susceptibility genes through SNP analyses and expression profiling using MALDI-TOF mass spectrometryQ33202394
Genotyping of sex hormone-related pathways in benign and malignant human prostate tissues: data of a preliminary studyQ33829149
Aromatase--a brief overviewQ34112633
Benign Prostatic Hyperplasia and Male Lower Urinary Tract Symptoms: Epidemiology and Risk FactorsQ34176834
Metabolic syndrome and benign prostatic enlargement: a systematic review and meta-analysisQ34408679
Impact of metabolic syndrome on response to medical treatment of benign prostatic hyperplasiaQ34698236
Metabolic syndrome and benign prostatic hyperplasia: evidence of a potential relationship, hypothesized etiology, and preventionQ35182377
Genetic polymorphisms and prostate cancer riskQ35597290
Does Metabolic Syndrome or its Components Correlate With Lower Urinary Tract Symptoms in Benign Prostatic Hyperplasia Patients?Q35957304
The relationships between metabolic syndrome, erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasiaQ35994047
Human aromatase: cDNA cloning, Southern blot analysis, and assignment of the gene to chromosome 15.Q36453370
Polymorphisms in genes involved in androgen pathways as risk factors for prostate cancerQ37397317
Benign prostatic hyperplasia: a new metabolic disease of the aging male and its correlation with sexual dysfunctions.Q37618958
Estrogen and androgen signaling in the pathogenesis of BPH.Q37828063
Burden of male lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) - focus on the UK.Q38198262
Metabolic syndrome: a closer look at the growing epidemic and its associated pathologiesQ38269343
Relationship between Metabolic Syndrome and Predictors for Clinical Benign Prostatic Hyperplasia Progression and International Prostate Symptom Score in Patients with Moderate to Severe Lower Urinary Tract SymptomsQ39649569
Correlation between prostate volume and single nucleotide polymorphisms implicated in the steroid pathwayQ39699530
Association of polymorphisms in CYP19A1 and CYP3A4 genes with lower urinary tract symptoms, prostate volume, uroflow and PSA in a population-based sample.Q39928318
Relative importance of sexuality and quality of life in patients with prostatic symptoms. Results of an international study.Q41454280
Letter to the editor: Impact of metabolic syndrome on response to medical treatment of benign prostatic hyperplasiaQ43125882
The association between polymorphisms in the CYP17 and 5alpha-reductase (SRD5A2) genes and serum androgen concentrations in men.Q43575799
Concurrent improvement of the metabolic syndrome and lower urinary tract symptoms upon normalisation of plasma testosterone levels in hypogonadal elderly men.Q46163361
Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placeboQ46974519
Genetic polymorphism in sex hormone metabolism and prostate cancer riskQ48972970
Association of metabolic syndrome and benign prostatic hyperplasia in Chinese patients of different age decades.Q51231420
Hormone concentration, metabolic disorders and immunoexpression of androgen and estrogen-alpha receptors in men with benign prostatic hyperplasia and testosterone deficiency syndromeQ61945860
Gender differences in the regulation of P450 aromatase expression and activity in human adipose tissueQ74083090
Effects of aromatase inhibition in hypogonadal older men: a randomized, double-blind, placebo-controlled trialQ81616161
P433issue4
P921main subjectprostatic hypertrophyQ506659
metabolic syndromeQ657193
P304page(s)568-578
P577publication date2018-06-05
P1433published inAndrologyQ26839702
P1476titleThe single nucleotide polymorphism rs700518 is an independent risk factor for metabolic syndrome and benign prostatic hyperplasia (MetS-BPH)
P478volume6

Search more.